- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06392009
A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients With Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II
Study Overview
Status
Intervention / Treatment
Detailed Description
Approximately 20 participants with TSC and 10 participants with FCD type II will be enrolled.
The effects of radiprodil are assessed in participants with treatment-resistant seizures (with or without behavioral symptoms). The daily doses of radiprodil will be individually titrated for every participant and all the participants will receive study drug.
This study is divided into the following periods:
PART A:
- Screening/Observation Period (up to six(6) weeks): Investigators assess eligibility followed by an Observation Period (at least four(4) weeks) to evaluate seizure frequency.
- Titration Period (approx. four(4) weeks): Radiprodil twice daily will be administered in escalating doses and plasma concentrations, safety, and tolerability assessed. Once a safe and potentially effective dose has been established, the participant will immediately enter the Maintenance Period.
- Maintenance Period (approx. twelve(12) weeks): The participant will continue to take the safe and potentially effective dose identified during the Titration Period. At the end of the Maintenance Period the participant will either be invited to enter Part B or the Tapering and Safety Follow-up Period.
- Tapering (15 days) and Safety Follow-up Period (14 days): a participant who doesn't take part in the long-term treatment period (Part B) will taper (ie gradually decrease) the study medicine for 15 days and enter a safety Follow-up Period (14 days). In this case, the participant will have one (1) last visit at the end of the safety Follow-up Period.
PART B:
- Long-Term Treatment Period (one(1) year): During the Long-Term Treatment Period (Part B), participants will continue taking radiprodil at the usual dose level and making regular visits to the study site.
- Tapering (15 days) and Safety Follow-up Period (14 days): at the end of the long-term treatment period (Part B), the participant will taper (ie gradually decrease) the study medicine for 15 days and enter a safety Follow-up Period (14 days) after his/her last dose of radiprodil. The participant will have one (1) last visit at the end of the safety Follow-up Period.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Clinical Operations
- Phone Number: +1-877-225-0014
- Email: ClinicalTrials@GrinTherapeutics.com
Study Locations
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Not yet recruiting
- Queensland Children Hospital
-
Principal Investigator:
- Catherine Riney
-
-
-
-
-
Antwerp, Belgium, 2650
- Not yet recruiting
- Universitair Ziekenhuis Antwerpen (UZA)
-
Leuven, Belgium, 3000
- Not yet recruiting
- University Hospitals Leuven, Pediatric Neurology
-
-
-
-
-
Toronto, Canada, M5G 1X8
- Not yet recruiting
- The Hospital for Sick Children (Sick Kids)
-
Vancouver, Canada, BC V6H 3N1
- Not yet recruiting
- BC Children's Hospital
-
-
Alberta
-
Calgary, Alberta, Canada, T3A 2X6
- Not yet recruiting
- Alberta Children's Hospital
-
-
-
-
-
Roma, Italy, 00165
- Recruiting
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
-
Roma, Italy, 00168
- Recruiting
- Universita Cattolica del Sacro Cuore - Policlinico Universitario "Agostino Gemelli"
-
-
Liguria
-
Genoa, Liguria, Italy, 16146
- Recruiting
- IRCCS Istituto Giannina Gaslini
-
-
Toscana
-
Florence, Toscana, Italy, 50139
- Recruiting
- AOU Meyer
-
-
-
-
-
Gdańsk, Poland, 80952
- Recruiting
- Uniwersyteckie Centrum Kliniczne
-
Kraków, Poland, 30363
- Recruiting
- Centrum Medyczne PLEJADY
-
Poznan, Poland, 60356
- Recruiting
- Uniwersytecki Szpital Kliniczny w Poznaniu
-
Warszawa, Poland, 04730
- Recruiting
- Instytut Pomnik - Centrum Zdrowia Dziecka
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitario Vall D´Hebron
-
Barcelona, Spain, 08950
- Recruiting
- Hospital Materno Infantil Sant Joan de Deu de Barcelona
-
Madrid, Spain, 28034
- Recruiting
- Hospital Ruber Internacional
-
Madrid, Spain, 28010
- Recruiting
- Hospital Universitario Vithas La Milagrosa
-
-
-
-
-
Bristol, United Kingdom, BS2 8BJ
- Not yet recruiting
- University Hospitals Bristol and Weston NHS Foundation Trust Bristol Royal Hospital for Children
-
Glasgow, United Kingdom, G51 4TF
- Not yet recruiting
- Royal Hospital For Children
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Failed to respond to at least 2 anti-seizure medications (ASMs) at appropriate dosages and duration.
Disease specific criteria:
- diagnosis of FCD Type II based on clinical symptoms and confirmed by a positive magnetic resonance imaging (MRI)
- diagnosis of TSC by either clinical or genetic diagnostic criteria (Northrup, 2021) as documented in the participant's medical record.
- Participant on average has had at least 8 countable/witnessed primary seizures during a 4-week baseline period with at least 1 seizure occurring in at least 3 of the 4 weeks of baseline
- All medical interventions for epilepsy / behavior (including ketogenic diet and any neurostimulation devices) should be stable for 28 days prior to screening with no more than 6 days per month use of rescue medication. Participants must remain on a stable regimen throughout the treatment period.
- Participant has had an MRI scan within 12 weeks of screening or during the screening period.
Exclusion Criteria:
- Any other clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder unrelated to TSC or FCD Type II that would preclude or jeopardize participant's safe participation or administration of study drug or the conduct of the study according to the judgement of the investigator.
- Clinically significant laboratory or ECG abnormalities.
- Severe hepatic dysfunction (Child-Pugh grade C).
- History of brain surgery within 6 months of enrollment for epilepsy or any other reason.
- Contraindications to radiprodil or with known hypersensitivity to the active substance or the excipients or other chemically closely related substances.
- Receiving treatment with contraindicated concomitant drugs such as agonists or antagonists of the glutamate receptor, including but not limited to felbamate, memantine, and perampanel.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TSC
Liquid suspension of radiprodil, at concentrations 0.25 mg/mL or 2.50 mg/mL for 1% and 10% formulation respectively.
It will be administered twice a day (bid) either orally or via gastric or nasogastric tube.
|
Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
|
Experimental: FCD Type II
Liquid suspension of radiprodil, at concentrations 0.25 mg/mL or 2.50 mg/mL for 1% and 10% formulation respectively.
It will be administered twice a day (bid) either orally or via gastric or nasogastric tube.
|
Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), Adverse Drug Reactions (ADRs), TEAEs Leading to Discontinuation and Severity of TEAEs
Time Frame: from Baseline to End-of-study: 1 year 6 months
|
Frequency, type, severity and duration of adverse events, serious adverse events and adverse drug reactions.
|
from Baseline to End-of-study: 1 year 6 months
|
Plasma concentration of radiprodil and maximum plasma concentration (Cmax)
Time Frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
|
Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
|
|
Plasma concentration of radiprodil versus time, area under the curve (AUCt)
Time Frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
|
Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
|
|
Pharmacokinetic plasma concentration of radiprodil: half-life (T1/2)
Time Frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
|
Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
|
|
Pharmacokinetic plasma concentration of radiprodil: time to Cmax (Tmax)
Time Frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
|
Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
|
|
Pharmacokinetic plasma concentration of radiprodil, clearance (Cl)
Time Frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
|
Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
|
|
Number of participants with abnormal laboratory tests results
Time Frame: from Baseline to End-of-study: 1 year 6 months
|
The clinical laboratory tests include Hematology, Serum Chemistry and Coagulation
|
from Baseline to End-of-study: 1 year 6 months
|
Number of participants with abnormal physical and neurological examination findings
Time Frame: Baseline, MV7, and in Part B: Month 3, 6, 9, 12: week 6, week 28, week 40, week 52, week 64, week 76
|
A complete physical and neurological examination according to standard of care excluding the genitourinary examination will be performed
|
Baseline, MV7, and in Part B: Month 3, 6, 9, 12: week 6, week 28, week 40, week 52, week 64, week 76
|
Clinically relevant changes in safety parameters: systolic blood pressure
Time Frame: from Baseline to End-of-study: 1 year 6 months
|
changes from Baseline to End of study for systolic blood pressure
|
from Baseline to End-of-study: 1 year 6 months
|
Clinically relevant changes in safety parameters: diastolic blood pressure
Time Frame: from Baseline to End-of-study: 1 year 6 months
|
changes from Baseline to End of study for diastolic blood pressure
|
from Baseline to End-of-study: 1 year 6 months
|
Clinically relevant changes in safety parameters: pulse rate
Time Frame: from Baseline to End-of-study: 1 year 6 months
|
changes from Baseline to End of Treatment for pulse rate
|
from Baseline to End-of-study: 1 year 6 months
|
12-Lead ECG: Mean change from Baseline to End-of-Treatment in RR interval
Time Frame: from Baseline to End-of-study: 1 year 6 months
|
from Baseline to End-of-study: 1 year 6 months
|
|
12-Lead ECG: Mean change from Baseline to End-of-Treatment in PR interval
Time Frame: from Baseline to End-of-study: 1 year 6 months
|
from Baseline to End-of-study: 1 year 6 months
|
|
12-Lead ECG: Mean change from Baseline to End-of-Treatment in QRS interval
Time Frame: from Baseline to End-of-study: 1 year 6 months
|
from Baseline to End-of-study: 1 year 6 months
|
|
12-Lead ECG: Mean change from Baseline to End-of-Treatment in QT interval
Time Frame: from Baseline to End-of-study: 1 year 6 months
|
from Baseline to End-of-study: 1 year 6 months
|
|
12-Lead ECG: Mean change from Baseline to End-of-Treatment in QTcF interval
Time Frame: from Baseline to End-of-study: 1 year 6 months
|
from Baseline to End-of-study: 1 year 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change from baseline in Video-EEG seizure burden
Time Frame: Baseline to end-of-treatment: week 6 to week 76
|
Assessed by 8- to 24- hour video electroencephalogram
|
Baseline to end-of-treatment: week 6 to week 76
|
Change from baseline in seizure frequency
Time Frame: Baseline to Maintenance Visit 7: week 6 to week 25 and Baseline to end-of-treatment: week 6 to week 76
|
assessed by seizure diaries
|
Baseline to Maintenance Visit 7: week 6 to week 25 and Baseline to end-of-treatment: week 6 to week 76
|
Change from baseline in number of seizure-free days and longest period with no seizures
Time Frame: Baseline to end-of-treatment: week 6 to week 76
|
assessed by seizure diaries
|
Baseline to end-of-treatment: week 6 to week 76
|
Aberrant Behavior Checklist-Community (ABC-2C)
Time Frame: Baseline to end-of-treatment: week 6 to week 76
|
The ABC-2C is a standardized 58-item caregiver-reported problem-behavior rating scale, originally designed to assess treatment effects in people with intellectual disabilities.
Each item is scored from 0 (never a problem) to 3 (severe problem).
Items load onto one of five empirically derived subscales: Irritability, Agitation, & Crying (15 items); Lethargy/Social Withdrawal (16 items); Stereotypic Behavior (7 items); Hyperactivity/Noncompliance (16 items); and Inappropriate Speech (4 items).
A total score would range from 0 to 174.
|
Baseline to end-of-treatment: week 6 to week 76
|
Caregiver Global Impression of Change (CaGI-C)
Time Frame: Baseline to end-of-treatment: week 6 to week 76
|
The CaGI-C is a 7-point caregiver-rated scale ranging from 1 (very much improved) to 7 (very much worse).
|
Baseline to end-of-treatment: week 6 to week 76
|
Clinical Global Impression of Change [CGI-C]
Time Frame: Baseline to end-of-treatment: week 6 to week 76
|
The CGI scale is a clinician-rated measures of change of a symptom or condition, using a single item, 6- or 7-point scale.
The CGI-C scale ranges from 1 ("Very much worse") to 7 ("Very much improved").
|
Baseline to end-of-treatment: week 6 to week 76
|
Pediatric Quality of Life Inventory [PedsQL]
Time Frame: Baseline to end-of-treatment: week 6 to week 76
|
The PedsQL is a 23-item generic health status instrument assessing 5 domains of health in children.
It's a 0-100 scale, and higher scores are indicative of better health-related quality of life.
|
Baseline to end-of-treatment: week 6 to week 76
|
Caregiver Burden Inventory (CBI)
Time Frame: Baseline to end-of-treatment: week 6 to week 76
|
The CBI is a validated scale providing information regarding the impact of caregiving on the lives of caregivers.
It comprises 24 closed questions divided into 5 dimensions.
Each dimension includes 4 or 5 items.
Each item is given a score between 0 and 4, where higher scores indicate greater caregiver burden.
|
Baseline to end-of-treatment: week 6 to week 76
|
Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: Baseline to end-of-treatment: week 6 to week 76
|
The C-SSRS is a validated tool designed to systematically evaluate the severity and intensity of suicidal ideation and behavior.
The scoring system ranges from 0 to 5 for suicidal ideation and from 0 to 25 for suicidal behavior, with higher scores indicating greater severity or greater frequency of suicidal thoughts or actions.
|
Baseline to end-of-treatment: week 6 to week 76
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neoplasms
- Neurologic Manifestations
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Neoplastic Syndromes, Hereditary
- Malformations of Cortical Development, Group I
- Nervous System Malformations
- Neurocutaneous Syndromes
- Hamartoma
- Neoplasms, Multiple Primary
- Sclerosis
- Seizures
- Behavioral Symptoms
- Tuberous Sclerosis
- Malformations of Cortical Development
- Focal Cortical Dysplasia
Other Study ID Numbers
- RAD-GRIN-201
- 2023-506301-20-00 (Other Identifier: CTIS)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberous Sclerosis Complex
-
Jazz PharmaceuticalsRecruitingTuberous Sclerosis Complex Associated Neuropsychiatric DiseaseUnited States, United Kingdom, Poland
-
Novartis PharmaceuticalsCompletedTuberous Sclerosis Complex-associated Refractory SeizuresUnited States, Colombia, Belgium, France, Japan, Taiwan, Turkey, Spain, Thailand, Korea, Republic of, Australia, Hungary, United Kingdom, Canada, Norway, Germany, Italy, Russian Federation, Denmark, Argentina, Netherlands, Greece, P... and more
-
Katarzyna KotulskaRecruitingTuberous Sclerosis ComplexPoland
-
University Hospitals Bristol and Weston NHS Foundation...University College, London; The Tuberous Sclerosis AssociationActive, not recruitingTuberous Sclerosis ComplexUnited Kingdom
-
University of California, Los AngelesBoston Children's HospitalCompletedTuberous Sclerosis ComplexUnited States
-
Children's Hospital Medical Center, CincinnatiMassachusetts General Hospital; The University of Texas Health Science Center... and other collaboratorsCompletedTuberous Sclerosis ComplexUnited States
-
Noema Pharma AGRecruitingTuberous Sclerosis ComplexUnited States, India, Israel, Turkey, Italy, Poland, Spain, United Kingdom
-
NobelpharmaActive, not recruitingTuberous Sclerosis ComplexJapan
-
Jazz PharmaceuticalsRecruitingSeizure in Participants With Tuberous Sclerosis Complex | Seizure in Participants With Dravet Syndrome | Seizure in Participants With Lennox-Gastaut SyndromeUnited States
-
Jazz PharmaceuticalsGW PharmaceuticalsCompletedSeizures | Tuberous Sclerosis ComplexUnited States
Clinical Trials on Radiprodil
-
UCB Biopharma S.P.R.L.TerminatedInfantile Spasms (IS)France
-
GRIN Therapeutics, Inc.RecruitingGRIN-related DisordersAustralia, United Kingdom, Spain, Netherlands, Germany, Italy, Canada
-
UCB Biopharma S.P.R.L.PRA Health SciencesCompletedHealthy VolunteersNetherlands